The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.
Dietary supplements and prostate cancer: A systematic review of double-blind, placebo-controlled ran
Dietary supplements and prostate cancer: A systematic review of double-blind, placebo-controlled randomised clinical trials - Abstract
Dietary supplements are popular among patients with prostate cancer (PC).
The objective of this systematic review was to critically examine double-blind, placebo-controlled randomised clinical trials (RCTs) of non-herbal dietary supplements and vitamins (NHDS) for evidence that prostate specific antigen (PSA) levels were reduced in PC patients. Five databases were searched from their inception through December 2012 to identify studies that met our inclusion criteria. Methodological quality was independently assessed by two reviewers using the Cochrane tool. Eight RCTs met the eligibility criteria and were of high methodological quality. The following supplements were tested: isoflavones (genistein, daidzein, and glycitein), minerals (Se) or vitamins (vitamin D) or a combination of antioxidants, bioflavonoids, carotenoids, lycopenes, minerals (Se, Zn, Cu, and Mg), phytoestrogens, phytosterols, vitamins (B2, B6, B9, B12, C, and E), and other substances (CoQ10 and n-acetyl-l cysteine). Five RCTs reported no significant effects compared with placebo. Two RCTs reported that a combination of antioxidants, isoflavones, lycopenes, minerals, plant oestrogens and vitamins significantly decreased PSA levels compared with placebo. One RCT did not report differences in PSA levels between the groups. In conclusion, the hypothesis that dietary supplements are effective treatments for PC patients is not supported by sound clinical evidence. There are promising data for only two specific remedies, which contained a mixture of ingredients, but even for these supplements, additional high quality evidence is necessary before firm recommendations would be justified.
Written by:
Posadzki P, Lee MS, Onakpoya I, Lee HW, Ko BS, Ernst E. Are you the author?
Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea; Complementary Medicine, Peninsula Medical School, University of Exeter, Exeter, UK. paul.posadzki@pcmd.ac.uk
Reference: Maturitas. 2013 Apr 5. pii: S0378-5122(13)00079-0.
doi: 10.1016/j.maturitas.2013.03.006
PubMed Abstract
PMID: 2356726
Discussion Boards
- All Discussion Boards
- 6 Cancer Survivors Network Information
- 6 Welcome to CSN
- 122.5K Cancer specific
- 2.8K Anal Cancer
- 456 Bladder Cancer
- 312 Bone Cancers
- 1.7K Brain Cancer
- 28.6K Breast Cancer
- 408 Childhood Cancers
- 28K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13.1K Head and Neck Cancer
- 6.4K Kidney Cancer
- 681 Leukemia
- 803 Liver Cancer
- 4.2K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 242 Multiple Myeloma
- 7.2K Ovarian Cancer
- 69 Pancreatic Cancer
- 493 Peritoneal Cancer
- 5.6K Prostate Cancer
- 1.2K Rare and Other Cancers
- 544 Sarcoma
- 743 Skin Cancer
- 659 Stomach Cancer
- 192 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.4K Lifestyle Discussion Boards